跳至主要内容
临床试验/JPRN-UMIN000015104
JPRN-UMIN000015104已完成未知

Prospective intervention study of novel SGLT-2 inhibitor ipragliflozin in patients with type 2 diabetes - Prospective intervention study of novel SGLT-2 inhibitor ipragliflozin in patients with type 2 diabetes

Seino Naika Clinic0 个研究点目标入组 100 人开始时间: 2014年9月10日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Type 1 diabetes 2) With severe ketosis, diabetic coma, or precoma within 6 months 3) With severe infection, pre or post surgery, and serious trauma 4) With moderate or severe renal dysfunction (Serum Creatinine male: >= 1.5mg/dL, female: >= 1.3mg/dL) 5) Has stroke, myocardial infarction, or other serious cardiovascular complications requireing hospitalization within 6 months 6) Is receiving SGLT-2 inhibitor at initiation 7) Is nursing or pregnant or planned to become pregnant 8) Has hypersensitivity to ipragliflozin or any other excipient of ipragliflozin 9) Considered as inadequate by the investigator

研究者

发起方
Seino Naika Clinic

相似试验